Zoetis Inc.

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Neutral +5

Here is Why Zoetis (ZTS) is One of the Best NYSE Stocks According Analysts

AI-generated analysis

Zoetis Inc. (NYSE:ZTS) reported first quarter 2026 financial results on May 7, with revenue of $2.3 billion reflecting a 3% reported increase but flat organic growth. Net income was $601 million and adjusted diluted EPS rose 9% to $1.53. CEO Kristin Peck highlighted a challenging...

Bullish Signals

  • Zoetis Q1 2026: $2.3B revenue, 9% EPS growth.
  • International segment: 17% revenue growth to $1.1B.
  • Livestock sales up 7% in US, 14% internationally.
  • 12+ potential blockbuster drugs in pipeline.

Bearish Signals

  • "The article suggests Zoetis offers less upside potential compared to AI stocks, explicitly carrying higher downside risk according to analyst comparisons." - Need to shorten while keeping ticker (Zoetis) and risk context.
  • "Q1 2026 revenue growth was flat on an organic basis despite a reported increase, indicating underlying sales weakness masked by accounting adjustments." - Q1 2026, flat organic growth.
  • "Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53, but this growth was noted against a challenging operating environment characterized by increased price sensitivity among pet owners." - Net income, but challenges - tricky for negative points since there's positive info. The negative is "challenging operating environment" and "price sensitivity.
2
Somewhat Bearish -25

Zoetis Cuts Outlook Following Challenging 1Q

AI-generated analysis

Zoetis, the animal health company listed under ticker ZTS, issued a downward revision to its full-year financial guidance following a disappointing first quarter performance that fell below analyst expectations. The stock price dropped approximately 7.8% in premarket trading and has declined about one-third of its...

Bullish Signals

  • Zoetis sharpens execution and drives cost management.
  • Revenue climbed 2.9% YoY to $2.26 billion.

Bearish Signals

  • Zoetis cut full-year guidance to $6.35-$6.50 from $6.65-$6.75.
  • Revenue projections lowered to $9.68B-$9.96B from prior $9.83B-$10.03B.
  • Q1 earnings dropped slightly to $601M vs $602M last year.
  • Adjusted Q1 EPS of $1.53 missed Wall Street's $1.60 target.
  • Q1 revenue of $2.26B missed the $2.3B consensus estimate.
  • Shares fell 7.8% premarket and lost one-third value in a year.
3
Very Bearish -75

Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut

AI-generated analysis

Zoetis Inc. (ZTS) shares experienced a significant selloff, plunging approximately 20% to close at $88.94 on Thursday, marking the weakest performance for any S&P 500 constituent that day and driving year-to-date losses to 29%. The sharp decline followed the company's first-quarter 2026 earnings report, which...

Bullish Signals

  • Zoetis EPS rose 9% year-over-year to $1.53.
  • International revenue surged 17% to $1.1 billion.
  • Parasiticides product line drove significant international expansion.
  • CEO Kristin Peck confirms decisive action for execution.

Bearish Signals

  • Shares plunged 20% to $88.94, worst S&P 500 performer.
  • Earnings of $1.53 missed the $1.60 forecast by $0.07.
  • Domestic sales fell 8% to $1.1 billion amid weak spending.
  • Companion animal category dropped 11% due to intense competition.
  • Management warned of headwinds including rising consumer cost consciousness.
  • International growth of 17% masked by non-recurring revenue.
  • Full-year EPS outlook cut to $6.85–$7.00 from $7.00–$7.10.
  • Revenue guidance lowered to $9.68B–$9.96B below prior expectations.
  • Stock down 29% year-to-date, near early 2019 levels.
4
Bullish +75

Zoetis Inc. KeyBanc Healthcare Forum: Targeting a $4B Renal Market and a $170 Price - TIKR.com

AI-generated analysis

Zoetis Inc. (ZTS) is adjusting its product strategy to address shifting veterinary care dynamics where routine visits are slowing but spending per visit has increased by 6%. CEO Kristin Peck highlighted that the company's blockbuster dermatology drug, Apoquel, faces unprecedented competitive pressure from cheaper generic...

Bullish Signals

  • Spending per visit jumped 6% as owners pay for premium care.
  • Livestock division growth outpaces historical 2% to 4% annual rate.
  • Injectables improve compliance and reduce monthly fees for pet owners.
  • AI genetics database selects molecules with fewer side effects than traditional methods.
  • $3B-$4B kidney drug targets massive unmet market need by 2031.
  • TIKR model projects $166.98 target price on 4.3% Revenue CAGR.
  • Model forecasts staggering 30.9% Net Income Margin highlighting profitability.
  • Injectables manufacturing costs less than pills, improving margins significantly.

Bearish Signals

  • Apoquel faces generic competition flooding the market.
  • Routine vet visits are slowing industry-wide.
  • Stock suffered a 32.20% max drawdown earlier this year.
  • Current $115.67 price may not reflect future potential.
5
Somewhat Bearish -40

Should You Buy Zoetis Stock At This Price?

Earnings report Guidance lowered AI-generated analysis

Zoetis (ZTS) stock is currently trading at a significant discount to the S&P 500 median, with a price-to-earnings multiple of 13.5 compared to 22.3 for the broader index. Over the past twelve months, shares have declined by 29.6%, leading some analysts to question whether the...

Bullish Signals

  • Operating margin of 37.7% outpaces S&P 500 median of 19.0%.
  • Trades at 12.4x operating cash flow vs 14.9x S&P 500.

Bearish Signals

  • Revenue growth stalled at 0.9% over four quarters ended Sep 2026.
  • Dermatology sales fell 16% worldwide as Apoquel lost market share.
  • Net income dropped to $2.51 billion despite rising operating income.
6
Bearish -50

Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire

AI-generated analysis

Zoetis Inc. (NYSE: ZTS) is the subject of a newly filed securities fraud class action lawsuit in the U.S. District Court for the Southern District of New York, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401...

Bearish Signals

  • Stock price fell 21.5% on May 7, 2026.
  • Librela growth weakening after FDA safety warnings.
  • Simparica Trio losing market share to cheaper rivals.
  • Apoquel and Cytopoint losing market share to competition.
7
Somewhat Bearish -45

Zoetis (ZTS) Stock Price Drops After Q3 Earnings Margin Pressure

Earnings report Guidance lowered AI-generated analysis

Zoetis (ZTS) shares dropped approximately 3% on the first trading day following its Q3 2026 earnings release, as investors reacted to significant pressure on profitability and softer full-year guidance. Quarterly net income excluding extra items fell to US$591 million from US$721 million in the prior...

Bullish Signals

  • Livestock revenue climbed 7% year over year.
  • Diagnostics sales rose 13%.
  • Operating costs remained flat on an adjusted basis.

Bearish Signals

  • Net income excluding items dropped 18.0% to US$591 million.
  • Adjusted gross margins compressed 0.6 percentage points to 71%.
  • Companion animal revenue fell 5%; dermatology sales plunged 16%.
  • Adjusted net income declined 7% organically due to cost gaps.
8
Somewhat Bearish -25

Goldman Sachs starts coverage: Zoetis stock gets a USD 74 target

Analyst downgrade Dividend AI-generated analysis

Goldman Sachs initiated coverage of Zoetis (ZTS) on October 17, 2026, assigning a Hold rating and a USD 74.00 price target. This target sits below the stock's recent trading price of approximately USD 79.32 as of mid-October, suggesting a neutral-to-negative near-term outlook from the analyst...

Bullish Signals

  • Livestock revenue grew 11% in Q2 2026.
  • International revenue rose 6% in Q2.
  • Diagnostics revenue increased 12% in Q2.

Bearish Signals

  • Adjusted net income declined 2% in Q2 2026.
  • Full-year organic revenue guidance revised to -3% to -1%.
  • Companion animal revenue fell 6% due to competition.
  • Goldman Sachs initiates with Hold rating and $74 target.
9
Bearish -65

Zoetis Inc. (NYSE: ZTS) Class Action Lawsuit Seeks Recovery - GlobeNewswire

AI-generated analysis

A securities fraud class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) in the U.S. District Court for the Southern District of New York, alleging material misstatements regarding product adoption and business prospects between January 14, 2025, and May 6, 2026. The complaint...

Bearish Signals

  • Lawsuit alleges false statements about product adoption and prospects.
  • Companion Animal business decline caused 21.5% stock drop on May 7, 2026.
  • Librela prescription growth weakening after FDA safety warnings.
  • Simparica Trio losing market share to lower-priced competitor.
  • Apoquel and Cytopoint losing market share to competition.
10
Very Bearish -75

Kaplan Fox Alerts Zoetis Inc. (NYSE: ZTS) Investors to a Securities Class Action Lawsuit - Deadline is July 27, 2026

AI-generated analysis

Kaplan Fox & Kilsheimer LLP has issued an alert regarding a securities class action lawsuit filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who acquired the company's securities between January 14, 2025 and May 6, 2026. The complaint alleges that Zoetis misled investors...

Bearish Signals

  • Securities lawsuit alleges Zoetis concealed safety concerns eroding sales.
  • Flagship Librela faces FDA warnings over dog neurological complications.
  • Simparica Trio loses market share to lower-priced competitor.
  • Dermatology products Apoquel and Cytopoint lose share to new rival.
  • Q1 2026 results deteriorated core business, reducing full-year guidance.
11
Somewhat Bearish -40

Zoetis (NYSE:ZTS) Misses Q1 CY2026 Revenue Estimates, Stock Drops 13%

AI-generated analysis

Zoetis (NYSE:ZTS), a global animal health company spun off from Pfizer in 2013, reported disappointing Q1 CY2026 financial results that led to an immediate 13% stock decline to $96.81. The company's Q1 revenue of $2.26 billion represented only 1.9% year-over-year growth, missing Wall Street estimates...

Bullish Signals

  • Zoetis is the world's largest pure-play animal health company globally.
  • Analysts expect revenue growth of 5.2% over the next 12 months.
  • The company maintains an elite operating margin of approximately 38.1%.
  • Zoetis repurchased stock, shrinking its share count by 11.6%.

Bearish Signals

  • Missed Q1 2026 revenue target of $2.31B with $2.26B sales.
  • Non-GAAP profit fell 5.3% below the $1.53 consensus estimate.
  • Full-year revenue guidance lowered to $9.82 billion from $9.93 billion.
  • Adjusted EPS guidance cut by 1.8% to $6.93 midpoint.
  • Operating margins shrank 4.6 points to 33.5% due to expenses.
12
Bullish +65

Zoetis Stock: Why 12 Pipeline Blockbusters Could Support a 40% Upside - TIKR.com

AI-generated analysis

Zoetis (ZTS) shares are trading at $125.93, nearly 29% below their 52-week high, despite the company beating Q4 revenue estimates by $27 million and acquiring Neogen's genomics business for $160 million on March 2. While certain franchises like Simparica, dermatology, and OA pain faced lighter-than-expected...

Bullish Signals

  • Beat Q4 revenue estimates by $27M with $1.48 adjusted EPS.
  • Simparica franchise hit $1.5B 2025 revenue with 12% operational growth.
  • Livestock segment delivered strong 8% organic operational growth in 2025.
  • Maintains robust 44.8% EBITDA margins despite competitive pressures.
  • Diverse pipeline of 12 potential blockbusters extends competitive lead.
  • Undervalued at $125.93 vs $178.4 TIKR model target by 2030.
  • Analyst consensus implies nearly 20% upside with mean target $151.

Bearish Signals

  • Franchises missed due to price sensitivity and tight budgets.
  • FDA approval intensifies dermatology competition for Numelvi.
  • Librela sales dropped 32% in Q4, threatening OA pain.
  • Analyst target $130 reflects Librela decline and softness.
13
Slightly Bullish +25

FDA approves Convenia RTU ahead of Q3 results for Zoetis stock

Analyst downgrade Dividend Drug approval AI-generated analysis

Zoetis (ZTS) received FDA approval for Convenia RTU, a ready-to-use antibiotic for dogs, on October 20, 2026. This new product adds to the company's companion-animal portfolio by offering up to 14 days of treatment from a single injection for bacterial skin infections like pyoderma and...

Bullish Signals

  • FDA approved Convenia RTU for 14-day canine treatment.

Bearish Signals

  • Jefferies downgraded to Hold, cut target from $103 to $83 due to pricing pressure.
14
Somewhat Bearish -25

Zoetis appoints Iris Knobloch to board as Zoetis stock holds value

Earnings report Guidance lowered Leadership change AI-generated analysis

Zoetis appointed Iris Knobloch to its board of directors on October 13, 2026, expanding the committee to 13 members effective December 1, 2026. The new director brings expertise in consumer strategy and digital transformation as the company navigates softer demand within its companion-animal segment. Zoetis...

Bullish Signals

  • Livestock segment grew 11% in Q2 2026.
  • International revenue rose 6% in Q2 2026.
  • Declared $0.53/share dividend on Oct 8, 2026.

Bearish Signals

  • US revenue fell 7% in Q2 2026.
  • FY2026 guidance reduced to 1-3% decline.
  • Companion-animal demand stabilization uncertain before Nov 5.
15
Slightly Bearish -20

Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?

AI-generated analysis

The article compares Pfizer and Zoetis, focusing on their divergent strategies regarding branded medicines. While Pfizer is acquiring replacements for drugs losing exclusivity to drive growth, Zoetis is facing a price war where it must cut effective prices to retain its franchises. This strategic divergence...

Bullish Signals

  • Operating margin of 37.6% exceeds Pfizer's 26.7%.
  • Livestock revenue grew 11% in Q2 2026.
  • Companion Animal Diagnostics grew 12% organically.
  • Averaged 5.0% revenue growth over three years.

Bearish Signals

  • Cut 2026 outlook; expects organic revenue decline of 1% to 3%.
  • Companion Animal sales trends show no market stabilization through July.
  • Q2 Companion Animal revenue fell 6%; Key Dermatology down 16%.
  • Forced gross-to-net investments and U.S. price adjustments vs generics.
  • New entrants erode pricing power via discounting and bundling.
16
Somewhat Bullish +45

Quality at the Right Price: Zoetis - marketscreener.com

AI-generated analysis

Zoetis (ZTS), the global leader in animal health, is facing a valuation re-rating as the market penalizes its stock for recent operational headwinds and a slowdown in demand. The company's shares have declined approximately 37% year-to-date and over 50% in twelve months, shifting investor perception...

Bullish Signals

  • Zoetis dominates segments with franchises stable for 20-30 years.
  • Companion animal segment drives nearly 68% of total revenue.
  • International sales surged 17% in the latest quarter.
  • Share buybacks increase from $1.1B in 2024 to $3.2B in 2025.
  • Total dividends rise to $889 million in 2025.
  • Net income grows from $2.49B in 2024 to $2.67B in 2025.
  • Forward P/E compresses to 20.9x for 2025 and 12.1x for 2026.

Bearish Signals

  • U.S. sales fell 8%; companion revenue down 11%.
  • Revenue guidance revised to $9.68B-$9.96B; EPS cut.
  • Organic growth flat, ending previous consistency streak.
  • Generics erode franchises like Convenia and Cerenia.
  • Librela sales decline signals high-value product weakness.
17
Slightly Bullish +15

Banque Transatlantique SA Trims Stake in Zoetis Inc. $ZTS

AI-generated analysis

Banque Transatlantique SA reduced its stake in Zoetis Inc. (NYSE:ZTS) by 26.2% during the fourth quarter, selling 62,912 shares to hold a remaining position of 176,793 shares valued at $22.24 million. While Banque Transatlantique trimmed its exposure, several other institutional investors increased their holdings, including...

Bullish Signals

  • T. Rowe Price increased stake by over 3,300%.
  • Insiders bought $886,384 worth in last three months.
  • Revenue grew 2.9% year-over-year to reach $2.26 billion.
  • Return on equity stands at robust 66.85%.
  • MidFirst Bank initiated new position valued at $633,000.

Bearish Signals

  • EPS of $1.53 missed $1.60 estimate by $0.07.
  • Revenue of $2.26B fell short of $2.30B target.
  • Analysts downgraded stock to 'Hold' due to caution.
  • Banque Transatlantique reduced stake by 26.2%.
18
Bearish -65

Class action lawsuit filed against Zoetis after stock drops 21.5% on weak Q1 results and lowered profit forecast - Pluang

AI-generated analysis

Pomerantz LLP has filed a class action lawsuit against Zoetis Inc. following the company's announcement on May 7, 2026, of flat Q1 net income and a lowered full-year profit forecast. The stock price subsequently dropped 21.5% after Zoetis cited a challenging environment characterized by reduced...

Bearish Signals

  • Profit forecast lowered for remainder of year.
  • Stock price dropped 21.5% after earnings.
  • Class action lawsuit alleges management fraud.
19
Somewhat Bearish -45

Zoetis cuts 2026 outlook as U.S. sales fall in Q1

AI-generated analysis

Zoetis Inc., the largest animal health company globally, reported first-quarter 2026 results that missed analyst expectations, causing its stock to drop approximately 13% in premarket trading. The core issue driving the decline was a significant drop in U.S. sales, which fell 4% sequentially and 7%...

Bullish Signals

  • Zoetis generated $2.3B Q1 2026 revenue.
  • Strong execution despite market headwinds.
  • Global footprint offsets US challenges.
  • Robust international presence supports growth.

Bearish Signals

  • Zoetis shares fell 13% premarket after outlook cut.
  • Q1 2026 U.S. revenue declined, driving downward guidance.
  • Total Q1 2026 revenue of $2.3B missed expectations.
20
Somewhat Bearish -35

Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?

Earnings report Guidance lowered AI-generated analysis

Zoetis Inc. (NYSE: ZTS) has experienced a sharp decline in valuation, losing over half its value and trading at a forward P/E of approximately 12x compared to 21.69x a year ago. This significant drop is driven by weaker demand in its U.S. companion-animal business, which...

Bullish Signals

  • Forward P/E dropped to 12x from 21.69x.
  • U.S. livestock sales surged 23% in Q2.
  • International revenue rose 8% organically.
  • Pipeline has 12+ candidates for high-value diseases.
  • Acquired VitalRADS to expand diagnostics.
  • Dectomax-CA1 got FDA approval for new use.

Bearish Signals

  • Reduced 2026 earnings expectations due to conservative growth view.
  • U.S. revenue fell 7% Q2; companion sales down 11%.
  • Organic revenue -1%; adjusted net income -2% slowdown.
  • Generic competition eroding Cerenia/Convenia share and pricing.